Introduction {#s0005}
============

Hepatitis C virus (HCV) infection is one of the major public health problems worldwide [@bb0005]. Chronic HCV infection is characterized by a high rate of progression to fibrosis, chronic hepatitis, leading to cirrhosis and ultimately to hepatocellular carcinoma (HCC) [@bb0010], [@bb0015], [@bb0020]. Although the relationship between HCV and the development of HCC is well established, the pathogenetic mechanism of hepatocarcinogenesis, including host- and viral-related factors, is still unknown. It is prudent to affirm that differences in the incidence rates and the strong gender distribution in HCC are not entirely due to differences in the exposure to the causative agents [@bb0025], [@bb0030]. Of great importance, genetic factors can also contribute, particularly gene polymorphisms of inflammatory cytokines and growth factor ligands and receptors [@bb0035].

Vitamin D is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses, fibrogenesis and development of cancer through vitamin D receptor (VDR) [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070]. Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the VDR gene, and some polymorphisms are associated with tumor occurrence [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]. For instance, VDR polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]. VDR polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis [@bb0085], [@bb0090], [@bb0095]. In a recent published study, VDR polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in patients with chronic hepatitis B [@bb0100].

So far, there are limited data in the literature on the association between VDR polymorphisms and the occurrence of HCC. In this present study, we investigated the role of VDR gene polymorphisms in the susceptibility and clinicopathological status of HCC in Chinese subjects with chronic HCV infection.

Patients and Methods {#s0020}
====================

Patients {#s0025}
--------

From August 2011 to July 2013, a total of 340 patients with chronic HCV infection receiving long-term follow up in a single center were enrolled. They included 201 chronic hepatitis, 47 cirrhosis and 92 HCC patients. All patients were seropositive for HCV antibody (by third-generation enzyme-linked immunosorbent array (ELISA) and HCV RNA (Amplicor™, Roche Diagnostics, Branchburg, NJ, USA). Patients were excluded if they were positive for serum hepatitis B surface antigen or anti-human immunodeficiency virus antibody, or exhibited other causes of hepatocellular injury (e.g. any history of alcoholism, autoimmune hepatitis, primary biliary cirrhosis and severe nonalcoholic liver disease with metabolic syndrome). During the same period, 100 healthy volunteers were collected as controls.

Pathologic diagnoses of chronic hepatitis or cirrhosis were made by percutaneous liver biopsies according to the modified Knodell histologic activity index [@bb0105], which were analyzed by pathologists who were blind to the patients' characteristics. Diagnosis of HCC was based on either the histopathologic findings in tumor tissues or typical HCC features of dynamic images if the nodules were larger than 1 cm in cirrhotic livers [@bb0110]. This study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of Chang Gung Memorial Hospital. All patients gave written informed consent before enrollment.

Detection of VDR Polymorphisms {#s0030}
------------------------------

The DNA was extracted from peripheral blood leukocytes using the Qiagen DNA isolation kit (Qiagen, Germany). The VDR genotype was determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms (RFLP) as previously described [@bb0115]. For the detection of BsmI polymorphisms, a forward primer in exon 7 (5'-CAACCAAGACTCAAGTACCGCGTCAGTGA-3') and a reverse primer in intron 8 (5'-AACCAGCGGAAGAGGTCAAGGG) was used. For the detection of ApaI and TaqI polymorphisms, a forward primer in exon 8 (5'-CAGAGCATGGACAGGGAGCAA) and a reverse primer in exon 9 (5'-GCAACTCCTCATGGCTGAGGTCTC) was used. The PCR products for BsmI polymorphisms were 820 base pair (bp), and for ApaI/TaqI polymorphisms they were 745 bp. The PCR mix contained 5 μL of each primer (10 pmol), 5 μL buffer, 1.5 μL MgCl~2~ (50 mM), 5 μL template DNA (50--100 ng), 5 μL dNTPs (2 mmol/L), Taq polymerase (MBI) 2 μL, H~2~O 26.5 μL. The DNA template was denatured at 95°C for 2 min. A total of 40 cycles of PCR were performed, consisting of a denaturation step for 45 sec at 94°C, an annealing step for 45 sec at optimum temperature (67°C for Apa I/Taq I and 60°C for Bsm I), and an extension reaction for 1 min at 72°C. A final extension step at 72°C for 2 min was added after the last PCR cycle.

After amplication, the PCR products were digested with BsmI, ApaI and TaqI endonucleases. Following restriction endonuclease digestion, genotyping was determined by ethidum bromide-UVB illumination of the fragments separated on gels of 2% agarose. The presence of BsmI, ApaI or TaqI restriction site was defined as the lower-case 'b', 'a' and 't', respectively, and the absence of the site was defined as the upper-case 'B', 'A' or 'T'. The BsmI restriction site resulted in two fragments (645 bp and 177 bp). Digestion with ApaI produced two fragments of 531 bp and 214 bp when the restriction site was present. Digestion with TaqI resulted in three fragments of approximately 205, 290 bp and 245 bp in the presence of TaqI polymorphic site, and in fragments of 245 and 495 bp in the absence of a TaqI polymorphic site.

Statistical Analysis {#s0035}
--------------------

Continuous data are expressed as mean ± standard deviation, and the categorical data are expressed as number (percentage). Comparisons of differences in the categorical date between groups were performed using the chi-square test. Distributions of continuous variables were analyzed by the Student's t-test or one-way ANOVA test with least significant difference (LSD) post-hoc correction between groups where appropriate. Stepwise logistic regression analysis was performed to assess the influence of each factor on the risk of developing HCC. All analyses were carried out using SPSS software version 15.0 (SPSS Inc., Chicago, IL). All tests were 2-tailed, and a p-value of less than 0.05 was considered statistically significant.

Results {#s0010}
=======

Baseline Features of the Studied Population {#s0040}
-------------------------------------------

The basic demographical and clinical features of the patients are shown in [Table 1](#t0005){ref-type="table"}. The mean age of HCC patients was significantly higher than those with cirrhosis, chronic hepatitis and controls (*P* \< 0.001). Patients with HCC had a higher male-to-female ratio than other groups (*P* = 0.001). There was no significant difference in BMI among these groups. The HCC subjects had lower platelet count compared to those with chronic hepatitis; whereas the platelet count was comparable between cirrhosis and HCC groups.Table 1Baseline Characteristics of the Studied PopulationCon (n = 100)CH (n = 201)LC (n = 47)HCC (n = 92)*P*-valueAge (years)52.7 ± 15.6^c^52.4 ± 11.5^e^55.9 ± 10.0^f^64.5 ± 11.6^cef^\<0.001Male gender (%)43 (43%)^c^101 (50%)^e^21 (45%)^f^64 (70%)^cef^0.001BMI (kg/m^2^)−24.6 ± 3.625.3 ± 3.624.2 ± 3.60.239AST (U/L)42 ± 33^abc^77 ± 58^ade^107 ± 41^bd^102 ± 80^ce^\<0.001ALT (U/L)50 ± 53^abc^138 ± 131^ae^147 ± 76^bf^94 ± 76^cef^\<0.001Platelet (10^4^/μL)−18.7 ± 5.4^ab^13.7 ± 6.1^a^13.2 ± 7.1^b^\<0.001[^1][^2][^3]

The Distribution of Frequencies of VDR Genotype and Haplotype {#s0045}
-------------------------------------------------------------

Firstly, HCC patients were compared with a control cohort of 100 healthy volunteers with regard to allelic frequency. The distribution of the alleles of BsmI, ApaI and TaqI was in accordance with the Hardy-Weinberg equilibrium in both individuals of HCC and controls (*P* \> 0.05 for any). Patients with HCC had a higher frequency of ApaI CC genotype (*P* = 0.027) and bAt\[CCA\]-haplotype consisting of BsmI C, ApaI C and TaqI A alleles (*P* = 0.037) as compared to control subjects. For the BsmI and TaqI polymorphisms, no significant associations were found.

[Figure 1](#f0005){ref-type="fig"} shows the association of VDR gene polymorphisms with the disease severity in chronic HCV infection. Patients carrying the corresponding ApaI CC genotype had a higher prevalence (34%) of HCC than those with CA (19.2%) or AA type (12.5%) (*P* = 0.024). In contrast, BsmI and TaqI polymorphisms were not significantly associated with disease severity of chronic HCV infection. As shown in [Table 2](#t0010){ref-type="table"}, patients with HCC carried a higher ratio of ApaI CC genotype compared to those with chronic hepatitis (*P* = 0.001) or cirrhosis (*P* = 0.026).Figure 1Association of VDR gene polymorphisms with the disease severity in chronic HCV infection. Bsm I (*P* = 0.343), Apa I (*P* = 0.024) and Taq I (*P* = 0.195).Table 2The Distribution of Frequencies of VDR Genotype and Haplotype Among Controls and Different Clinical Stages of Chronic HCV InfectionCon (n = 100)CH (n = 201)LC (n = 47)HCC (n = 92)BsmI (rs1544410) TT0 (0%)0 (0%)0 (0%)0 (%) TC11 (11%)13 (6%)6 (13%)7 (8%) CC89 (89%)188 (94%)41 (87%)85 (92%) T vs. C allele11:18913:3896:887:177ApaI (rs7975232) CC55 (55%)[a](#tf0005){ref-type="table-fn"}102 (51%)^b^24 (51%)^c^65 (71%)^abc^ CA40 (40%)^d^82 (41%)^e^19 (40%)24 (26%)^de^ AA5 (5%)17 (8%)4 (9%)3 (3%) C vs. A allele150:50^f^286:116^g^67:27^h^154:30^fgh^TaqI (rs731236) GG0 (0%)0 (0%)0 (0%)0 (0%) AG14 (14%)15 (7%)7 (15%)6 (7%) AA86 (86%)186 (93%)40 (85%)86 (93%) G vs. A allele14:18615:3877:876:178BsmI--ApaI--TaqI TAG (BaT)10 (10%)12 (6%)5 (11%)5 (5%) CCA (bAt)54 (54%)^i^102 (51%)^j^24 (51%)^k^64 (70%)^ijk^ CAA (bat)31 (31%)83 (41%)^l^15 (32%)21 (23%)^l^ CAG (baT)4 (4%)3 (1%)2 (4%)0 (0%) TAA (Bat)0 (0%)1 (1%)1 (2%)1 (1%) TCG (BAT)0 (0%)0 (0%)0 (0%)1 (1%) TCA (BAt)1 (1%)0 (0%)0 (0%)0 (0%) CCA vs. TAG & CAA54:41^m^102:95^n^24:2064:26^mn^[^4][^5][^6]

Factors Associated with Developing HCC by Logistic Regression Analysis {#s0050}
----------------------------------------------------------------------

As shown in [Table 3](#t0015){ref-type="table"}, univariate analysis revealed that age, male gender, lower platelet count (\<15 × 10^4^/μL), the carriage of bAt\[CCA\]-haplotype and ApaI CC genotype were factors significantly associated with developing HCC. Stepwise logistic regression analysis showed that age (odds ratio (OR): 1.10, 95% confidence interval (CI): 1.07-1.14, *P* \< 0.001), male gender (OR: 3.90, 95% CI: 2.07-7.35, *P* \< 0.001), low platelet count (\<15 × 10^4^/μL)(OR: 4.20, 95% CI: 2.26-7.83, *P* \< 0.001) and the carriage of ApaI CC genotype (OR: 2.77, 95% CI: 1.47-5.21, *P* = 0.002) were the independent predictors.Table 3Univariate Analyses and Stepwise Multivariate Analyses of Factors Associated with the Risk of HCC in Patients with Chronic HCV InfectionUnivariate AnalysesStepwise Multivariate AnalysesOdds Ratio (95% CI)*P*-valueOdds Ratio (95% CI)*P*-valueAge (per 1 year increase)1.10 (1.07-1.13)\<0.0011.10 (1.07-1.14)\<0.001Male gender2.36 (1.42-3.93)0.0013.90 (2.07-7.35)\<0.001BMI0.96 (0.89-1.03)0.212Platelet (\<15 × 10^4^/μL)4.36 (2.59-7.34)\<0.0014.20 (2.26-7.83)\<0.001CCA vs. TAG&CAA2.25 (1.33-3.78)0.002−−BsmI CC type1.01 (0.41-2.48)0.987−−ApaI CC type2.33 (1.40-3.89)0.0012.77 (1.47-5.21)0.002TaqI AA type1.40 (0.55-3.56)0.486−−[^7]

Comparison Between Chronic HCV Patients with Apa I CC Type and CA/AA Type {#s0055}
-------------------------------------------------------------------------

Since ApaI CC genotype was a significant factor associated with developing HCC, we thus compared the chronic hepatitis C patients with ApaI CC type and CA/AA type. As shown in [Table 4](#t0020){ref-type="table"}, patients carrying ApaI CC genotype had a higher prevalence of HCC and pre-existing cirrhosis and a higher ratio of BsmI CC type and TaqI AA type as compared to those with ApaI CA/AA type.Table 4Comparison Between Chronic HCV Patients with ApaI CC Type and CA/AA TypeApaI CC (*N* = 191)ApaI CA/AA type (*N* = 149)*P*-valueAge (years)55.8 ± 12.756.6 ± 12.20.600Male gender (%)106 (55%)80 (54%)0.412BMI (kg/m^2^)24.6 ± 3.224.6 ± 4.10.908LC\*85 (45%)50 (34%)0.026HCC65 (34%)27 (18%)0.001AST (U/L)83 ± 5796 ± 780.139ALT (U/L)131 ± 133123 ± 830.522Platelet (10^4^/μL)16.1 ± 6.317.0 ± 6.80.153BsmI CC type190 (99%)124 (83%)\<0.001TaqI AA type190 (99%)122 (82%)\<0.001[^8][^9]

Discussion {#s0015}
==========

Hepatocarcinogenesis is a complex and multi-factorial process, in which both environmental and genetic features interfere and contribute to malignant transformation [@bb0120]. The identification of genetic factors related to HCC susceptibility may improve our understanding of the various biological pathways involved in hepatocarcinogenesis and as well improve the scientific basis for preventative intervention. Numerous candidate-gene studies have reported associations between single nucleotide polymorphism and the development of HCC [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140]. In this study, we investigated the possible association between the VDR gene polymorphisms and HCC in a Chinese population with chronic HCV infection. Our data showed that patients with HCC had a higher frequency of ApaI CC genotype and bAt\[CCA\]-haplotype as compared to control subjects. Furthermore, stepwise logistic regression analyses revealed that ApaI CC genotype was an independent factor, suggesting that the ApaI C polymorphisms may be used as a molecular marker to predict the risk of HCC in the patients infected with HCV.

Association studies of several polymorphisms in the VDR gene have been performed to investigate their implication with severity of chronic liver disease [@bb0085], [@bb0090], [@bb0095], [@bb0100]. One of the common genetic variations of VDR gene is the bat-haplotype consisting of BsmI, ApaI and TaqI [@bb0145]. These genetic variations have been described as important modulators of several chronic liver diseases such as primary biliary cirrhosis and autoimmune hepatitis [@bb0090], [@bb0095]. Recently, bAt \[CCA\]-haplotype VDR polymorphisms have been reported to influence antiviral response to peginterferon plus ribavirin therapy in chronic hepatitis C [@bb0150], [@bb0155]. In particular, Baur et al. have demonstrated that bAt\[CCA\]-haplotype and ApaI CC genotype are both significantly associated with a rapid fibrosis progression rate and with the presence of cirrhosis in patients with chronic hepatitis C [@bb0160]. This result was similar to that in our study showing that patients carrying ApaI CC genotype had a higher prevalence of cirrhosis compared to those with ApaI CA/AA type if the HCC patients with pre-existing cirrhosis were enrolled for analysis. Moreover, our data further showed that ApaI C polymorphisms might not only affect the fibrosis progression and the presence of cirrhosis, but also have a direct association with HCC development in chronic HCV infection.

Two recent studies have reported the relationship between VDR gene polymorphisms and HCC development in patients with chronic HCV infection [@bb0165], [@bb0170]. Falleti et al. have demonstrated that VDR genetic polymorphisms are significantly associated with the occurrence of HCC in cirrhotic patients who underwent liver transplantation [@bb0165]. However, this relationship is more specific for patients with an alcoholic etiology, but not in those with cirrhosis of viral origin. This discrepancy could be explained by the limited case numbers in the subgroup analysis of virus-cirrhotic subjects. The other study has reported that genetic variations in CYP2R1, GC, and DHCR7 are associated with progression to HCC in patients with chronic hepatitis C according to four heterogeneous independent cohorts [@bb0170].

In this study, we cannot prove the causal relationships between genetic variations and distinct clinical phenotypes. However, the significant association between the polymorphisms in VDR which serves as the physiological target to mediate vitamin D effects and HCV-induced HCC suggests that an impaired vitamin D metabolism contributes to hepatocarcinogenesis in chronic HCV infection. Although serum vitamin D levels and history regarding vitamin D intake (dietary or supplemental) were not available, this could be justified since VDR gene variants modulate biological effects of vitamin D without influencing vitamin D plasma levels [@bb0145], [@bb0175]. In addition, 25(OH)D3 serum levels strongly fluctuate during seasons, with age, and as a consequence of numerous other conditions [@bb0040], [@bb0180].

In conclusion, the present study suggests a significant association of VDR ApaI polymorphism with the development of HCC in chronic HCV infection. The characterization of VDR genetic polymorphisms in HCV carriers may help to identify those who are at high risk of developing HCC. This observation needs to be validated in further studies.
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[^1]: Data are expressed as mean ± standard deviation or number (percentage).

[^2]: *P*-value by one-way ANOVA test or *x*^2^ test; ^a^ Significant differences between Con and CH; ^b^ Significant differences between Con and LC; ^c^ Significant differences between Con and HCC; ^d^ Significant differences between CH and LC; ^e^ Significant differences CH and HCC; ^f^ Significant differences between LC and HCC with LSD post-hoc correction or *x*^2^ test.

[^3]: Abbreviation: Con: healthy control; CH: chronic hepatitis; LC: liver cirrhosis; HCC: hepatocellular carcinoma; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

[^4]: Data are expressed as number (percentage). *P*-value by *x*^2^ test or Fisher's exact test;

[^5]: Abbreviation: VDR, vitamin D receptor; Con: healthy control; CH: chronic hepatitis; LC: liver cirrhosis; HCC: hepatocellular carcinoma.

[^6]: *P* = 0.027; ^b^*P* = 0.001; ^c^*P* = 0.026; ^d^*P* = 0.047; ^e^*P* = 0.018; ^f^*P* = 0.044; ^g^*P* = 0.001; ^h^*P* = 0.019; ^i^*P* = 0.037; ^j^*P* = 0.003; ^k^*P* = 0.041; ^l^*P* = 0.002; ^m^*P* = 0.048; ^n^*P* = 0.002

[^7]: Abbreviations: HCC: hepatocellular carcinoma; HCV, hepatitis C virus; CI, confidence interval; BMI: body mass index.

[^8]: Data are expressed as mean ± standard deviation or number (percentage). *P*-value by Student's *t*-test or *x*^2^ test. \*Analysis included 47 LC patients without HCC and 88 HCC patients with underlying LC.

[^9]: Abbreviations: HCV: hepatitis C virus; BMI: body mass index; LC: liver cirrhosis; HCC: hepatocellular carcinoma; AST, aspartate transaminase; ALT, alanine transaminase.
